Roche signed to develop superbug killer
Zurich: Pharmaceuticals colossal Roche announced that it had joined forces with fellow Swiss company Polyphor to develop an antibiotic to fight a superbug that is increasing disease as per recorded by the hospitals.
Hospital-acquired infections are a major global concern, causing 25,000 deaths a year in the European Union alone.
They are blamed on factors such as sloppy hygiene practices, the inappropriate use of drugs which has enabled resistant bacteria to thrive, and contact between humans and animals, either directly or via the food chain.
The contract is signed by Roche regarding an exclusive worldwide licensing with Polyphor to develop and commercialise the latter’s experimental antibiotic POL7080.
The drug’s target is the Pseudomonas aeruginosa bacteria, which can give rise to life-threatening infections and usually occurs in patients in hospital, as well as members of the broader public who have weakened immune systems.
Pseudomonas aeruginosa accounts for one in every 10 hospital-acquired infections in the United States and is listed as one of the six most dangerous drug-resistant microbes.
This disease is mainly caused at urinary tract, respiratory system, joints and bones, and digestive system.
The disease is a major hazard for patients suffering with cancer, AIDS, severe burns, and chronic infections such as cystic fibrosis.
The general antibiotics cannot control such type of diseases due to rise in antibiotic conflict.
It is expected that Polyphor will gain double digit revenues on the sales of this product.